Metabolomics is the large-scale study of small molecule metabolites within biological systems. In neurodegeneration research, metabolomics provides a functional readout of cellular metabolism and has emerged as a powerful approach for discovering [biomarkers](/mechanisms/biomarkers-neurodegeneration), understanding disease mechanisms, and identifying therapeutic targets.
Metabolomics is the large-scale study of small molecule metabolites within biological systems. In neurodegeneration research, metabolomics provides a functional readout of cellular metabolism and has emerged as a powerful approach for discovering [biomarkers](/mechanisms/biomarkers-neurodegeneration), understanding disease mechanisms, and identifying therapeutic targets.
Overview
Mermaid diagram (expand to render)
Metabolomics complements [genomics](/mechanisms/genetics), [proteomics](/mechanisms/proteomics-overview), and [transcriptomics](/mechanisms/transcriptomics-neurodegeneration) by measuring the end products of cellular processes. The metabolome reflects the combined influence of genetic variation, environmental factors, and disease pathology, making it particularly valuable for understanding complex [neurodegenerative disorders](/diseases/alzheimers-disease) like [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD)[@patti2012].
Metabolic Biomarkers in Neurodegeneration
Alzheimer's Disease
Multiple metabolite alterations have been identified in AD:
[Sphingolipids](/mechanisms/sphingolipid-metabolism-alzheimers): Ceramide and sulfatide reductions correlate with cognitive decline[@cheng2023]
[Phosphatidylcholines](/mechanisms/lipid-metabolism-neurodegeneration): Decreased in AD plasma and CSF[@whiley2021]
[Amino acids](/mechanisms/amino-acid-metabolism-neurodegeneration): Altered glutamate, GABA, and tryptophan metabolism[@gonzlezdomnguez2015]
[Organic acids](/mechanisms/organic-acid-metabolism-neurodegeneration): Elevated lactate and decreased alpha-ketoglutarate in AD brain[@mahajan2022]
Parkinson's Disease
PD-specific metabolic changes include:
[Uric acid](/mechanisms/urate-neuroprotection-parkinsons): Lower levels associated with increased PD risk[@weisskopf2007]
[Coenzyme Q10](/mechanisms/coq10-neurodegeneration): Decreased in PD patients and linked to [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)[@shults2002]
[Glutathione](/mechanisms/glutathione-neurodegeneration): Reduced in [substantia nigra](/brain-regions/substantia-nigra) of PD patients[@sian1994]
Metabolome-Wide Association Studies (MWAS)
MWAS examine the relationship between the metabolome and disease phenotypes. Key findings include:
Identification of novel [biomarker panels](/biomarkers/alzheimers-disease-biomarkers) for AD diagnosis[@arnold2020]
Detection of [metabolic signatures](/mechanisms/disease-metabolic-signatures) that predict disease progression[@tynkkynen2018]
Integration with [genetic data](/mechanisms/genetics) to identify causal metabolites[@shin2014]
Analytical Methods
Nuclear Magnetic Resonance (NMR)
[NMR spectroscopy](/technologies/nmr-spectroscopy-neurodegeneration) offers several advantages for metabolomics:
[Chen et al. 2024: Spatial multimodal analysis of transcriptomes and metabolomes in tissues — metabolomics in neurodegenerative disease (2024)](https://pubmed.ncbi.nlm.nih.gov/37667091/)
References
[Kaddurah-Daouk R, Weinshilboum RM, Pharmacometabolomics: implications for clinical pharmacology (2014)](https://pubmed.ncbi.nlm.nih.gov/24193171/)
[Patti GJ, Yanes O, Siuzdak G, Metabolomics: the apogee of the omics trilogy (2012)](https://pubmed.ncbi.nlm.nih.gov/22475752/)
[Cheng H, Wang M, Li JL, et al, Sphingolipid metabolism in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37648975/)
[Whiley L, Langford J, Zetterberg H, et al, Metabolomic biomarkers for Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33395168/)
[González-Domínguez R, García-Barrera T, Gómez-Ariza JL, Metabolomic approaches to investigate metabolic alterations in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25916546/)
[Mahajan UV, Varma VR, Huang J, et al, Metabolomic signatures of Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35245482/)
[Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A, Plasma urate and risk of Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17468177/)
[Shults CW, Oakes D, Kieburtz K, et al, Effects of coenzyme Q10 in early Parkinson disease (2002)](https://pubmed.ncbi.nlm.nih.gov/12163726/)
[Sian J, Dexter DT, Lees AJ, et al, Glutathione depletion in the substantia nigra (1994)](https://pubmed.ncbi.nlm.nih.gov/7978540/)
[Arnold M, Nho K, Kueider-Paisley A, et al, Metabolomics for Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32830206/)
[Tynkkynen J, Chouraki V, van der Lee SJ, et al, Metabolic profiling of incident diabetes (2018)](https://pubmed.ncbi.nlm.nih.gov/30104762/)
[Shin SY, Fauman EB, Petersen AK, et al, An atlas of genetic influences on human blood metabolites (2014)](https://pubmed.ncbi.nlm.nih.gov/24816252/)
[Emwas AH, The strengths and weaknesses of NMR spectroscopy and mass spectrometry (2015)](https://pubmed.ncbi.nlm.nih.gov/26030424/)
[Dettmer K, Aronov PA, Hammock BD, Mass spectrometry-based metabolomics (2007)](https://pubmed.ncbi.nlm.nih.gov/17982442/)
[Lin MT, Beal MF, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases (2006)](https://pubmed.ncbi.nlm.nih.gov/17005044/)
[Zheng H, Zhang C, Luo W, et al, CSF neurotransmitter metabolites in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34365849/)
[Mapstone M, Cheema AK, Fiandaca MS, et al, Plasma phospholipids identify antecedent memory impairment (2014)](https://pubmed.ncbi.nlm.nih.gov/25100165/)
[Ryu do Y, Song SH, Lee KA, et al, Blood metabolomics for biomarker discovery in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32868679/)
[Suhre K, Shin SY, Petersen AK, et al, Human metabolic individuality in biomedical and pharmaceutical research (2011)](https://pubmed.ncbi.nlm.nih.gov/21849506/)
[Krumsiek J, Suhre K, Illig T, Adamski J, Theis FJ, Bayesian multivariate analysis of metabolomics data (2011)](https://pubmed.ncbi.nlm.nih.gov/21677137/)
[Patti GJ, Tautenhahn R, Rinehart D, et al, A view from on high: NIST metabolomics standards (2012)](https://pubmed.ncbi.nlm.nih.gov/23179867/)
[Kaddurah-Daouk R, Kristal BS, Weinshilboum RM, Metabolomics: a global biochemical approach to drug response and disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18319048/)